Evidence map›Paper›PMID 36077517›Full record

ArticleInternational journal of molecular sciences2022

Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells.

Qiuyu Liu, Wanda van der Stel, Vera E van der Noord, Hanneke Leegwater, Bircan Coban, Kim Elbertse, Joannes T M Pruijs, Olivier J M Béquignon, Gerard van Westen, Sylvia E Le Dévédec and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Qiuyu LiuLeiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.ORCID 0000-0003-0622-266X
Wanda van der StelLeiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.ORCID 0000-0001-8289-7189
Vera E van der NoordLeiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.ORCID 0000-0002-9894-3239
Hanneke LeegwaterLeiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.ORCID 0000-0001-6003-1544
Bircan CobanLeiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.
Kim ElbertseLeiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.
Joannes T M PruijsLeiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.
Olivier J M BéquignonLeiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.ORCID 0000-0002-7554-9220
Gerard van WestenLeiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.ORCID 0000-0003-0717-1817
Sylvia E Le DévédecLeiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.ORCID 0000-0002-0615-9616
Erik H J DanenLeiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.ORCID 0000-0002-0491-6345
Leiden University · NL

Funding

China Scholarship Council 201706550007Dutch Cancer Society 10967
6 · The paper itself

Abstract

Hypoxia and HIF signaling drive cancer progression and therapy resistance and have been demonstrated in breast cancer. To what extent breast cancer subtypes differ in their response to hypoxia has not been resolved. Here, we show that hypoxia similarly triggers HIF1 stabilization in luminal and basal A triple negative breast cancer cells and we use high throughput targeted RNA sequencing to analyze its effects on gene expression in these subtypes. We focus on regulation of YAP/TAZ/TEAD targets and find overlapping as well as distinct target genes being modulated in luminal and basal A cells under hypoxia. We reveal a HIF1 mediated, basal A specific response to hypoxia by which TAZ, but not YAP, is phosphorylated at Ser89. While total YAP/TAZ localization is not affected by hypoxia, hypoxia drives a shift of [p-TAZ(Ser89)/p-YAP(Ser127)] from the nucleus to the cytoplasm in basal A but not luminal breast cancer cells. Cell fractionation and YAP knock-out experiments confirm cytoplasmic sequestration of TAZ(Ser89) in hypoxic basal A cells. Pharmacological and genetic interference experiments identify c-Src and CDK3 as kinases involved in such phosphorylation of TAZ at Ser89 in hypoxic basal A cells. Hypoxia attenuates growth of basal A cells and the effect of verteporfin, a disruptor of YAP/TAZ-TEAD-mediated transcription, is diminished under those conditions, while expression of a TAZ-S89A mutant does not confer basal A cells with a growth advantage under hypoxic conditions, indicating that other hypoxia regulated pathways suppressing cell growth are dominant.

Indexed as

Transcriptional Coactivator with PDZ-Binding Motif ProteinsTriple Negative Breast NeoplasmsHumansHypoxiaPhosphoproteinsPhosphorylationTranscription FactorsYAP-Signaling ProteinsPhosphoproteinsTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsWWTR1 protein, humanYAP-Signaling Proteinsbasal A triple negative cellsbreast cancerhypoxiaphosphorylationTAZ

Identifiers

PMID36077517
PMCPMC9456181
OpenAlexW4294733398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.